Minimal residual disease in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Minimal Residual Disease (MRD) is a key prognostic factor in multiple myeloma, influencing treatment decisions and patient outcomes.
• Despite advanced therapies, complete eradication of malignant plasma cells remains difficult.
• Sensitive detection methods are essential for identifying residual disease.

Purpose of the Study:

• To highlight the prognostic significance of MRD in multiple myeloma.
• To discuss the role of MRD negativity in predicting patient survival and guiding treatment adjustments.
• To address the challenges and future directions in MRD monitoring.

Main Methods:

• Utilizing sensitive techniques such as next-generation flow cytometry (NGF) and next-generation sequencing (NGS) for MRD detection.
• Analyzing the association between MRD status and clinical outcomes like progression-free survival (PFS) and overall survival (OS).
• Reviewing current and emerging therapeutic strategies in multiple myeloma.

Main Results:

• MRD negativity is strongly associated with improved PFS and OS in multiple myeloma patients.
• Sustained MRD negativity predicts prolonged survival and supports treatment de-escalation.
• MRD status can guide therapy escalation for high-risk individuals.

Conclusions:

• MRD is a vital biomarker for predicting outcomes and personalizing treatment in multiple myeloma.
• Standardization of MRD testing and accessibility remain critical challenges.
• Future research should focus on refining MRD-guided therapies and exploring novel detection methods like liquid biopsies.